Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Jun 15, 2012

NEW YORK (GenomeWeb News) – Mark Boguski, a faculty member at the Harvard Medical School and Beth Israel Deaconess Medical Center, has co-founded a new consulting company called Genome Health Solutions.

The new company offers expertise in five areas — genomic medicine readiness assessments; genomic technology selection and management; genomic comparative effectiveness programs; individual case management; and social media optimization.

Boguski founded the Genomic Medicine Initiative at Beth Israel Deaconess, and he previously was a researcher using genomics and bioinformatics at Johns Hopkins University School of Medicine and the National Institutes of Health and a VP at Novartis.

Sequenom said in a document filed with the US Securities and Exchange Commission that shareholders re-elected its board of directors to hold office until the annual meeting next year. Those re-elected are Ernst Günter Afting; Kenneth Buechler; John Fazio; Harry Hixson; Richard Lerner; Ronald Lindsay; David Pendarvis; and Charles Slacik.

Transgenomic has appointed Matthew Beer as vice president of business development for oncology; and John McAuliffe as vice president of business development for neurology.

Beer was previously director of oncology marketing and hematology/oncology life cycle leader at Quest Diagnostics. Prior to that, he was vice president of business development at Caris Life Sciences. He has also worked for Abbott, Targeted Molecular Diagnostics, and Oncotech. He holds a BS in microbiology from the University of Iowa.

McAuliffe previously worked at HistoRx, where he served as vice president of sales. Prior to that, he was director of business development at Athena Diagnostics.

GenMark Diagnostics said this week that Stephen Worland has been appointed to its board of directors.

Worland is currently president and CEO of Effector Therapeutics. He was president and CEO and a director of Anadys Pharmaceuticals from 2007 until the company was acquired by Roche in 2011. He began his healthcare industry career in 1988 at Agouron Pharmaceuticals.

The European Personalised Medicine association, or EPEMED, has appointed Emmanuelle Benzimra as its new general delegate in Luxembourg, where the organization is based.

Benzimra, who co-founded the philanthropic organization Bench2Cures, "has a broad experience in various sectors including the finance and investment banking industry, non-profit start-ups and philanthropic organizations,” EPEMED said in a statement.

EPEMED also appointed three new board members: Patrizia Luchetta, director of new technologies at the Ministry of the Economy and of Foreign Trade for the Grand Duchy of Luxembourg; Werner Verbiest, global head of Janssen Diagnostics; and Peter Collins, VP and head of diagnostics at GlaxoSmithKline.

The association also appointed Jami Taylor, global policy leader for Janssen Diagnostics, as vice chair of the education committee and Janssen’s designated representative on EPEMED’s board of directors.

Microtest Diagnostics has named Kjell Kristiansen as group managing director.

Kristiansen joins Microtest from Phadia, where he was regional director for Asia for 14 years. Thermo Fisher acquired Phadia last year. London-based Microtest said it made the appointment as it prepares to launch its microarray-based ADAM in vitro allergy and autoimmunity testing platform. has appointed Paul Billings to its board of directors. Billings has also been named a member of the company's audit committee.

Billings is currently chief medical officer at Life Technologies. He also was CEO of Cellective Dx and senior vice president of Laboratory Corporation of America.

Knome has appointed Gary Cohen as senior vice president, general counsel, and secretary.

Cohen joins the firm from Foundation Medicine, where he held the position of vice president of bioethics, law, and policy. Previously, he held legal and bioethics roles at a number of life science companies, including Millennium Pharmaceuticals, Genzyme Transgenics, and the Genetics Institute.

BG Medicine said this week in an SEC filing that Pieter Muntendam has resigned from his posts as executive VP and chief medical officer to pursue other opportunities. Muntendam was the company's CEO for six years before he left that post early this year and was replaced by Eric Bouvier.

The company also said that at its annual stockholder meeting this week it re-elected three members of its board of directors, including Noubar Afeyan, Stelios Papadopoulos, and Harrison Bains.

Protein analysis company BioScale has appointed Martin Latterich as chief scientific officer.

Latterich recently was a professor at the Proteogenomics Research Institute for Systems Medicine in San Diego, and has held senior management positions at several biotech firms including Diversa and Illumina, where he headed the proteomics inititiaves. He is CSO, co-founder, and a board member for the Nicholas Conor Institute for Pediatric Cancer Research, and he formerly served on the faculty at the University of Montreal, McGill University and the Salk Institute.

The Institute for Systems Biology has appointed Robert Lipshutz to be chief business officer and senior VP for strategic partnerships.

Lipshutz spent nearly two decades at Affymetrix in various roles focusing on business development, licensing, diagnostics, and emerging markets, and most recently as senior VP for corporate development.

Marijn Dekkers has been elected to the General Electric's board of directors. Dekkers, has been chairman of the board at Bayer since 2010, and he formerly worked at Thermo Fisher Scientific and Honeywell, and spent a decade at General Electric.

Molecular diagnostic company Crescendo Bioscience has tapped Oscar Segurado to be chief medical officer, David Chernoff to be senior VP of medical affairs, and Rebecca Bolce as director of medical affairs.

Segurado will oversee growth and clinical development of Vectra DA, the company's test for RA disease and R&D for other auto-immune and inflammatory tests. He most recently was VP of clinical development and medical affairs at Becton Dickinson Biosciences, and he worked at Abbot Global Pharmaceutical Research and Development.

Bolce joins Crescendo after spending 19 years at Janssen Services.

Genomic Health shareholders have re-elected the company's board of directors, including Julian Baker; Fred Cohen; Samuel Colella; Ginger Graham; Randall Livingston; Woodrow Myers; Kimberly Popovits; and Randal Scott.

Illumina said in an SEC filing this week that Christian Cabou, who is senior VP, general counsel and secretary, has notified the company that he plans to retire sometime early next year.

Pacific Biosciences' stockholders have voted to re-elect Michael Hunkapiller, Randy Livingston, and Marshall Mohr to continue serving on its board of directors as class II directors.

Saladax Biomedical has appointed Kevin Harter to be president and CEO, starting on June 18.

Harter has been serving as interim CEO since earlier this year, when he replaced Edward Erickson, who resigned from both positions but retained his spot on the company's board of directors.

Harter was executive chairman at Saladax from 2007 to 2011, and he formerly co-founded Keystone Medical Systems and he held several positions at Pennsylvania Blue Shield.

Promoted? Changing jobs? GenomeWeb wants to know. E-mail [email protected] to appear in People In The News, a weekly roundup of industry comings and goings.